Interferon-γ-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis

Blood

Volumn 95, Issue 7, 2000, Pages 2329-2336

  Berthou, Christian ^b   Bourge, Jean François ^b   Zhang, Yuehe ^b   Soulié, Annie ^b   Geromin, Daniela ^b   Denizot, Yves ^b   Sigaux, François ^b   Sasportes, Marilyne ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; PHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ARTICLE; CELL ACTIVATION; CELL DAMAGE; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; TUMOR CELL;

EID: 0034177040     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2329.007k34_2329_2336     Document Type: Article

References (52)

1. Philipps JH, Chang C, Mattson J, Gumperz JE, Paerham P, Lanier LL. CD94 and a novel associated protein (94AP) from a NK cell receptor involved in the recognition of HLA-A, -B, and -C allotypes. Immunity. 1996;5:163.
2. Lanier LL. NK cells: from no receptors to too many. Immunity. 1997;6:371.
3. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. Human killer cell activatory receptors for MHC class I molecules are induced in a multimeric complex expressed by natural killer cells. J Immunol. 1997;158:5083.
4. Kärre K, Colonna M. Specificity, Function, and Development of NK cells. Berlin, Germany: Springer; 1998.
5. Kägi D, Ledermann B, Bürki K, Seiler P, Odermat KJ. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31.
6. Kägi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528.
7. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370: 650.
8. Lowin B, Beermann F, Schmidt A, Tschopp J. A null mutation in the perforin gene impairs cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1994;91:11,571.
9. Walsh CM, Matloubian M, Liu CC, et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A. 1994;91:10,854.
10. Simon MM, Hausmann M, Tran T, et al. In vitro-and ex vivo-derived cytolytic leukocytes from granzymes A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med. 1997;186:1781.
11. van den Broek MF, Kägi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol. 1995;25:3514.
12. van den Broek MF, Kägi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781.
13. Podack ER, Hengartner H, Lichtenheld MG. A central role of perforin in cytolysis? Annu Rev Immunol. 1991;9:129.
14. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1994;1:343.
15. Liu CC, Persechini PM, Young JDE. Perforin and lymphocyte-mediated cytolysis. Immunol Rev. 1995;146:145.
16. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 1996;14:207.
17. Pinkoski MJ, Hobman M, Heibein JA, et al. Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. Blood. 1998;92:1044.
18. Trapani JA, Jans P, Smyth MJ, et al. Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Diff. 1998; 5:488.
19. Blink EJ, Trapani JA, Jans JA. Perforin-dependent nuclear targeting of granzymes: a central role in the nuclear events of granule-exocytosis-mediated apoptosis? Immunol Cell Biol. 1999;77: 206.
20. Jans DA, Jans P, Briggs LJ, Sutton V, Trapani JA. Nuclear transport of granzyme B (fragmentin-2): dependence of perform in vivo and cytosotic factors in vitro. J Biol Chem. 1996;271:30,781.
21. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell. 1997;90:13.
22. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell. 1994;76:977.
23. Shresta S, MacIvor DM, Heusel JW, Russel JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci U S A. 1995;92:5679.
24. Uellner R, Zvelebil MJ, Hopkins J, et al. Perform is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 1997;16:7287.
25. Müller C, Tschopp J. Resistance of CTL to perforin-mediated lysis: evidence for a lymphocyte membrane protein interacting with perform. J Immunol. 1994;153:2470.
26. Liu CC, Persechini PM, Young JDE. Expression and characterization of functionally active recombinant perform produced in insect cells. J Immunol. 1996;156:3292.
27. Yue CC, Reynolds CW, Henkart PA. Inhibition of cytolysin activity in large granular lymphocyte granules by lipids: evidence for a membrane insertion mechanisms of lysis. Mol Immunol. 1987; 24:647.
28. Ojcius DM, Young JDE. Characterization of the inhibitory effect of lysolipids on perforin-mediated hemolysis. Mol Immunol. 1990;27:257.
29. 2+-dependent receptor molecule for lymphocyte perform. Nature. 1989;337:272.
30. Antia R, Schlegel RA, Williamson P. Binding of perforin to membranes is sensitive to lipid spacing and not headgroup. Immunol Lett. 1992;32: 153.
31. Rochel N, Cowan JA: Dependence of the lytic activity of the N-terminal domain of human perforin on membrane lipid composition: implication for T-cell self-preservation. Eur J Biochem. 1997; 249:223.
32. Nakamura M, Honda ZI, Izumi T, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem. 1991;266:20,400.
33. Honda ZI, Nakamura M, Miki I, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 1991;349: 342.
34. Kunz D, Gerard NP, Gerard C. The human leukocyte platelet-activating factor receptor. J Biol Chem. 1992;267:9101.
35. + T cells upon NKR-P1 cross-linking. J Immunol. 1996; 183:2391.
36. Oshimi Y, Oda S, Honda Y, Nagata S, Miayazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996;157:2909.
37. Berthou C, Legros-Maida S, Soulié A, et al. Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes. Blood. 1995;85:1540.
38. Le Gouill C, Parent JL, Rola-Plezczynski M, Stankova J. Structural and functional requirements for agonist-induced internalization of the human platelet-activating factor receptor. J Biol Chem. 1997;272:21,289.
39. 3H]SR 27417, on guinea-pig tracheal epithelilal cells. Biochem J. 1992;284:201.
40. 3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes. J Lipid Mediat. 1993;7:57.
41. Dupuis F, Levasseur S, Jean-Louis F, et al. Production, metabolism and effect of platelet-activating factor on the growth of the human K562 erythroid cell line. Biochim Biophys Acta. 1997;1359: 241.
42. Denizot Y, Trimoreau F, Dupuis F, Verger C, Praloran V. PAF and haematopoiesis. III. Presence and metabolism of platelet-activating factor in human bone marrow. Biochim Biophys Acta. 1995; 1265:55.
43. Clément MV, Legros-Maïda S, Soulié A, Guillet J, Sasportes M. Dissociation of natural killer and lymphocyte-activated killer cell lytic activities in human CD3- large granular lymphocytes. Eur J Immunol. 1993;23:697.
44. Schnelder C, Newman RA, Sutherland DR, Asser U, Greaves MF. A one step purification of membrane proteins using a high efficiency immunomatis. J Biol Chem. 1982;257:10,766.
45. Berthou C, Michel L, Soulié A, et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol. 1997;159:5293.
46. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375.
47. + and Fas tumor cells. Blood. 1998;92:4248.
48. Jiang S, Ojcius DM, Persechini PM, Young JDE. Resistance of lymphocytes to perforin-mediated killing: inhibition of perform binding activity by surface membrane proteins. J Immunol. 1990;144: 998.
49. Ghadially FN. Cell membrane and coat. In: Ghadially, FN. ed. Ultrastructural Pathology of the Cell and Matrix. Vol. 2. 3rd ed. Butterworths, England; 1988:1043.
50. Travers JB, Shaw JE, Li Q, Kniss DA, Fertel RH. Evidence for platelet-activating factor receptors in several B lymphoblastoid cell lines. Life Sci. 1991;49:1755.
51. Garcia MC, Garcia C, Gijon MA, Fernandez-Gallardo S, Mollinedo F, Sanchez Crespo M. Metabolism of platelet-activating factor in human haematopoietic cell lines: differences between myeloid and lymphoid cells. Biochem J. 1991; 273:573.
52. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M. Perforin and IFN-γ are involved in the antitumor effects of antibody-targeted superantigens. J Immunol. 1998; 160:5309.